Navigation Links
Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
Date:1/7/2008

es that may cause results to differ materially from those set forth in these statements. Among other things these risks and uncertainties include, but are not limited to, changing research and business priorities of Maxygen, the inherent uncertainties of pharmaceutical research and drug development, our ability to develop human therapeutic drugs in an increasingly competitive biotechnology industry and the uncertain timing of such development, the development of superior products by competitors, and our ability to establish and maintain our manufacturing arrangements. These and other risk factors are more fully discussed in our Form 10-K for the year ended December 31, 2006, including under the caption "Risk Factors", and in our other periodic SEC reports, all of which are available from Maxygen at http://www.maxygen.com. Maxygen disclaims any obligation to update or revise any forward-looking statement contained in this release as a result of new information or future events or developments.

Neulasta(R) is a registered trademark of Amgen Inc.


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
6. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
9. FASgen Announces a New Discovery in Obesity Research
10. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
11. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 16, 2014 Eight finalists, all representing outstanding ... present their proposals for a chance to compete for ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation Symposium ... on Friday, Oct. 24, 2014. Selected from ... the US and internationally, the finalists are: ...
(Date:10/16/2014)... 16, 2014 Curtis & Coulter LLC, a ... away from hosting their co-located Bioequivalence: Intersection Between ... Formulation Innovations Summit taking place on November 5-6 ... November,s events are specifically designed ... the bioequivalence testing process, as well as optimizing formulation ...
(Date:10/16/2014)... 2014  Personna Industrial, the world,s leading manufacturer of ... and safety systems will be exhibiting at the MD&M ... on October 29-30th. Personna Industrial,s booth is #847. MD&M ... for medical device design and manufacturing professionals. The MD&M ... and applications that are redefining the medical device manufacturing ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personna Industrial Exhibiting Among Top Suppliers To Medical Industry At MD&M Minneapolis 2
... public health, and regulatory highlights for this week from ... document is designed for credentialed journalists. Release dates and ... 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... any regulatory or enforcement actions due to legal limitations. ...
... YORK,  June 6, 2011 Aeolus Pharmaceuticals, Inc. (OTCQB: ... is available for on-demand viewing. LINK: ... button. Aeolus Pharmaceuticals, presentation will be available ... the "virtual trade booth" for the next three weeks. ...
Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:10/19/2014)... (PRWEB) October 19, 2014 According to ... (NINDS) the vast majority of adults (up to ... point in their lives, spending at least $50 billion ... pain includes; spinal instability, stenosis, spondylolisthesis, and symptomatic degenerative ... by wear and tear associated with the aging process, ...
(Date:10/18/2014)... Riverdale, NY (PRWEB) October 19, 2014 ... Center, specializing in long-term and rehabilitation care in the ... Carlos G. Beato, chief executive officer, was honored by ... with the CHA Corporate Alumni award at their 30th ... science degree in healthcare administration from New Jersey City ...
(Date:10/18/2014)... October 19, 2014 The ... that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), JustHost and ... in 2014. , “There are thousands ... but good suppliers are not too many. ... FatCow are the most outstanding suppliers when ...
(Date:10/18/2014)... October 19, 2014 Web hosting provides ... in websites in recent years, and the new demand ... web hosting companies that offer a variety of different ... USA has compared a lot of professional Windows web ... Bluehost ( http://www.bluehost.com/track/seohosts ), InMotion and Arvixe are the ...
(Date:10/18/2014)... College of Neuropsychopharmacology (ECNP) is pleased to announce that ... Dick Swaab, for his book, We are our Brains: ... ECNP Media Award recognises outstanding contributions to destigmatising disorders ... of € 5,000. , The ECNP Media Award was ... a better understanding of the complexity and impact of ...
Breaking Medicine News(10 mins):Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 2Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 5Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 2Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 3Health News:Top10BestSEOHosting.com: Best Reseller Hosting Companies Announced 2Health News:Best Web Hosting Companies In 2014 Released By SEO Hosting Review Site Best Cheap Hosting USA 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... (iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. Indicated for a wide ... flexibility by providing a wide range of ...
... MR contrast agent FDA-approved for administration by ... based, IV contrast media for MR imaging ... has convenient packaging options for just ... efficient, problem-free delivery. You can trust OptiMARK® ...
... contrast agent approved for sale in the ... the Amersham Health portfolio to include an ... aids in the detection, localization, characterization, and ... within minutes of injection, and additional scans ...
Medicine Products: